Hypercalcemia Treatment MarketThe global hypercalcemia treatment market is on track for significant growth, with an estimated valuation of USD 18.07 billion in 2023. The market is projected to expand ...
Amgen investors have been focused on prospects for MariTide, which activates the appetite- and blood sugar-reducing hormone ...
UBS forecasts that Sandoz will likely achieve the lower end of its 24-26% core EBITDA margin target by 2028. To reach the ...
Josh Canavan, PharmD, head of pharmacy at RazorMetrics, recommends key educational resources for biosimilars, and emphasizes the extensive research conducted before pharmacy benefit managers (PBMs) ...
Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the ...
The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.
January saw almost every major cardiovascular subspecialty represented among our most-clicked stories of the month.
Alongside margin recovery, Biocon Biologics has also gained market share, with oncology remaining a key focus area.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback